Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 11/20 | 0.41 |
| ▸ | CNR1 | P21554 | 7/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14605638 | 1.00 | CAPN1 (0.46) | CAPN1CNR2CNR1FPR2BCHE | |
| SCHEMBL13872588 | 0.99 | CAPN1 (0.46) | CAPN1CNR2CNR1FPR2CACNA1B | |
| SCHEMBL4133234 | 0.90 | CAPN1 (0.46) | CAPN1CNR2CNR1FPR2CACNA1B | |
| SCHEMBL4128166 | 0.90 | CAPN1 (0.46) | CAPN1CNR2CNR1BCHECACNA1B | |
| SCHEMBL4130510 | 0.89 | CAPN1 (0.47) | CAPN1CNR2CNR1FPR2CACNA1B | |
| SCHEMBL4131294 | 0.89 | CAPN1 (0.47) | CAPN1CNR2CNR1BCHECACNA1B | |
| SCHEMBL5429669 | 0.88 | CAPN1 (0.44) | CAPN1CNR2CNR1BCHECACNA1B | |
| SCHEMBL4135412 | 0.88 | CAPN1 (0.45) | CAPN1CNR2CNR1BCHE | |
| SCHEMBL5439592 | 0.87 | CAPN1 (0.45) | CAPN1CNR2CNR1BCHECACNA1B | |
| SCHEMBL4129702 | 0.87 | CAPN1 (0.45) | CAPN1CNR2CNR1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CAPN1 2031/4885CNR2 57/4885CNR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.